ARS Pharmaceuticals (SPRY) Operating Margin (2022 - 2026)
ARS Pharmaceuticals recorded quarterly Operating Margin of 265.18% in Q1 2026, down 173.02% quarter-over-quarter from 363.14% in Q4 2025, and up 20111.0% year-over-year from N/an in Q1 2025.
ARS Pharmaceuticals' Operating Margin history runs 5 years deep, the most recent figure standing at 265.18% for Q1 2026.
- In Q1 2026, Operating Margin rose 20111.0% year-over-year to 265.18%; the TTM figure through Mar 2026 stood at 59.56% (down 3169.0% YoY), while the FY2025 annual figure was 42.7%, down 3924.0% from the prior year.
- Operating Margin came in at 265.18% for Q1 2026 at ARS Pharmaceuticals, down from 363.14% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 363.14% in Q4 2025 to a low of 206030.0% in Q2 2023.
- A 5-year average of 23880.08% and a median of 1051.64% in 2024 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin tumbled 20466276 bps in 2023 and jumped 20296200 bps in 2024, its largest moves.
- ARS Pharmaceuticals' Operating Margin stood at 3507.94% in 2022, then sank by 5773 bps to 206030.0% in 2023, then surged by 100 bps to 54.51% in 2024, then soared by 566 bps to 363.14% in 2025, then plunged by 173 bps to 265.18% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 265.18%, 363.14%, and 163.66% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | ARS Pharmaceuticals | 900.62 Mn | 699.65 Mn | - | -265.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -265.18% |
| Dec 31, 2025 | 363.14% |
| Sep 30, 2025 | -163.66% |
| Jun 30, 2025 | -302.95% |
| Mar 31, 2025 | -466.29% |
| Dec 31, 2024 | 60.08% |
| Sep 30, 2024 | -1,051.64% |
| Jun 30, 2024 | -3,068.00% |
| Jun 30, 2023 | -206,030.00% |
| Mar 31, 2023 | -93,565.00% |
| Sep 30, 2022 | -3,507.94% |
| Jun 30, 2022 | -1,367.24% |
| Mar 31, 2022 | -1,070.74% |